Examination of Setarud (IMOD™) in the Management of Patients with Severe Sepsis

Overview

Journal Daru

Specialty Pharmacology

Date 2012 May 23

PMID 22615589

Citations 16

Authors

A Mahmoodpoor

K Eslami

M Mojtahedzadeh

A Najafi

A Ahmadi

A Dehnadi-Moghadam

A Mohammadirad

M Baeeri

M Abdollahi

Affiliations

Soon will be listed here.

Abstract

Background And The Purpose Of The Study: Analysis of current immunomodulating strategies indicates that monovalent approaches are unlikely to restore immunostasis or achieve complete therapy of sepsis. Setarud (IMOD) as a mixture of urtica, carotenoids, urea, and selenium has been recently patented for its potential in reduction of Tumor Necrosis Factor alpha (TNF-α) and Interferon-γ and Interleukin-2 levels. The aim of this study was to examine efficacy of IMOD in the management of patients with severe sepsis.

Methods: Twenty patients with severe sepsis and acute physiology and chronic health evaluation (APACHE) score of more than 20 were randomized to receive standard treatment of severe sepsis (control group) or standard treatment plus IMOD (IMOD group). The group treated with IMOD for 14 days was according to the pilot study and regarding the stability of patient's conditions in the ICU. Of course patients in both groups received standard treatment and all were monitored for 28 days. Blood samples were analyzed for interleukins (IL-1, IL-2, IL-6), plasminogen activator inhibitor (PAI-1), TNF-α, total thiol molecules (TTM), nitric oxide (NO), total antioxidant power (TAP), and lipid peroxidation (LPO). Daily APACHE, Sequential Organ Failure Assessment (SOFA), and Simplified Acute Physiology Score (SAPS) were calculated.

Results And Major Conclusion: Comparing with controls, IMOD was significantly effective in improving SAPS, SOFA, and APACHE scores, and reduction of mortality rate. Among tested inflammatory biomarkers, IMOD significantly improved TTM and TNF-α values. It is concluded that IMOD might be added as a safe adjutant to standard treatment of severe sepsis.

Citing Articles

Effects of Herbal Compound (IMOD) on Behavior and Expression of Alzheimer's Disease Related Genes in Streptozotocin-Rat Model of Sporadic Alzheimer's Disease.

Bazazzadegan N, Shasaltaneh M, Saliminejad K, Kamali K, Banan M, Khorshid H Adv Pharm Bull. 2017; 7(3):491-494.

PMID: 29071234 PMC: 5651073. DOI: 10.15171/apb.2017.060.

Effect of Septimeb as a new natural extract on severe sepsis: A randomized clinical trial.

Pourdast A, Sanaei M, Jafari S, Mohammadi M, Khalili H, Shafiee G Caspian J Intern Med. 2017; 8(1):35-43.

PMID: 28503281 PMC: 5412247.

Functional Foods for Health: The Interrelated Antioxidant and Anti-Inflammatory Role of Fruits, Vegetables, Herbs, Spices and Cocoa in Humans.

Serafini M, Peluso I Curr Pharm Des. 2016; 22(44):6701-6715.

PMID: 27881064 PMC: 5427773. DOI: 10.2174/1381612823666161123094235.

Neuroprotective Effects of Herbal Extract (Rosa canina, Tanacetum vulgare and Urtica dioica) on Rat Model of Sporadic Alzheimer's Disease.

Daneshmand P, Saliminejad K, Shasaltaneh M, Kamali K, Riazi G, Nazari R Avicenna J Med Biotechnol. 2016; 8(3):120-5.

PMID: 27563424 PMC: 4967545.

Protective Effect of Selenium-Based Medicines on Toxicity of Three Common Organophosphorus Compounds in Human Erythrocytes In Vitro.

Fakhri-Bafghi M, Ghasemi-Niri S, Mostafalou S, Navaei-Nigjeh M, Baeeri M, Mohammadirad A Cell J. 2016; 17(4):740-747.

PMID: 26862533 PMC: 4746424. DOI: 10.22074/cellj.2016.3846.

References

Ansari G, Mojtahedzadeh M, Kajbaf F, Najafi A, Khajavi M, Khalili H . How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. Adv Ther. 2008; 25(7):681-702. DOI: 10.1007/s12325-008-0075-1. View

Patwardhan B, Gautam M . Botanical immunodrugs: scope and opportunities. Drug Discov Today. 2005; 10(7):495-502. PMC: 7128543. DOI: 10.1016/S1359-6446(04)03357-4. View

Herzum I, Renz H . Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem. 2008; 15(6):581-7. DOI: 10.2174/092986708783769704. View

Damas P, Canivet J, De Groote D, Vrindts Y, Albert A, Franchimont P . Sepsis and serum cytokine concentrations. Crit Care Med. 1997; 25(3):405-12. DOI: 10.1097/00003246-199703000-00006. View

Ospina-Tascon G, Buchele G, Vincent J . Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail?. Crit Care Med. 2008; 36(4):1311-22. DOI: 10.1097/CCM.0b013e318168ea3e. View

Warren H, Amato S, Fitting C, Black K, Loiselle P, Pasternack M . Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med. 1993; 177(1):89-97. PMC: 2190862. DOI: 10.1084/jem.177.1.89. View

Martin G, Mannino D, Eaton S, Moss M . The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348(16):1546-54. DOI: 10.1056/NEJMoa022139. View

Reinhart K, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J . Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med. 1996; 24(5):733-42. DOI: 10.1097/00003246-199605000-00003. View

Veleminsky Jr M, Stransky P, Veleminsky Sr M, Tosner J . Relationship of IL-6, IL-8, TNF and sICAM-1 levels to PROM, pPROM, and the risk of early-onset neonatal sepsis. Neuro Endocrinol Lett. 2008; 29(3):303-11. View

10.

Hack C, Aarden L, Thijs L . Role of cytokines in sepsis. Adv Immunol. 1997; 66:101-95. DOI: 10.1016/s0065-2776(08)60597-0. View

11.

Kornblit B, Munthe-Fog L, Madsen H, Strom J, Vindelov L, Garred P . Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome. Crit Care. 2008; 12(3):R83. PMC: 2481482. DOI: 10.1186/cc6935. View

12.

Angus D, Lidicker J, Clermont G, Carcillo J, Pinsky M . Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29(7):1303-10. DOI: 10.1097/00003246-200107000-00002. View

13.

Astaneie F, Afshari M, Mojtahedi A, Mostafalou S, Zamani M, Larijani B . Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res. 2005; 36(4):376-81. DOI: 10.1016/j.arcmed.2005.03.007. View

14.

Fekade D, Knox K, Hussein K, Melka A, Lalloo D, Coxon R . Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med. 1996; 335(5):311-5. DOI: 10.1056/NEJM199608013350503. View

15.

Wang H, Bloom O, Zhang M, Vishnubhakat J, Ombrellino M, Che J . HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285(5425):248-51. DOI: 10.1126/science.285.5425.248. View

16.

Santolaya M, Alvarez A, Aviles C, Becker A, King A, Mosso C . Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. Pediatr Infect Dis J. 2008; 27(6):538-43. DOI: 10.1097/INF.0b013e3181673c3c. View

17.

Chen X, Li W, Wang H . More tea for septic patients?--Green tea may reduce endotoxin-induced release of high mobility group box 1 and other pro-inflammatory cytokines. Med Hypotheses. 2005; 66(3):660-3. PMC: 1447554. DOI: 10.1016/j.mehy.2005.09.025. View